-
Gemtuzumab ozogamicin, sold
under the
brand name Mylotarg®, is an antibody-drug
conjugate (a drug-linked
monoclonal antibody) that is used to
treat acute...
-
Inotuzumab ozogamicin, sold
under the
brand name Besponsa, is an antibody-drug
conjugate medication used to
treat relapsed or
refractory B-cell precursor...
- The term
ozogamicin in the
names of
monoclonal antibodies or antibody-drug
conjugates indicates that they are
linked to a
cytotoxic agent from the class...
- to
their targeting properties. In 2001 Pfizer/Wyeth's drug
Gemtuzumab ozogamicin (trade name: Mylotarg) was
approved based on a
study with a surrogate...
-
expression is
known to be tied to TREM2. CD33 is the
target of
gemtuzumab ozogamicin (trade name: Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories), an antibody-drug...
-
Ozogamicin:
Reintroduction Based on
Favorable Risk:Benefit Profile". ADCReview.
September 2, 2017.
Retrieved August 14, 2024. "Gemtuzumab
Ozogamicin (Mylotarg®)...
- (AML). A
second calicheamicin-linked
monoclonal antibody,
inotuzumab ozogamicin (marketed as Besponsa), an anti-CD22-directed antibody-drug conjugate...
- the
differentiating promyelocytes. The
monoclonal antibody,
gemtuzumab ozogamicin, has been used
successfully as a
treatment for APL,
although it has been...
-
systemic approaches. The
first approved drug of this type was
gemtuzumab ozogamicin (Mylotarg),
released by
Wyeth (now Pfizer). The drug was
approved to treat...
-
Targeted conditions Year
approved (FDA) Year
approved (EMA)
Inotuzumab ozogamicin (Besponsa) Anti-CD22
monoclonal antibody-drug
conjugate Relapsed or refractory...
